PETALING JAYA: Duopharma Biotech Bhd
is expected to have a solid year in 2023, driven by higher insulin contracts, new products and reinvestment allowance incentives.
All of this is anticipated to help mitigate cost pressures from rising overnight policy rates, electricity tariffs and labour costs, said TA Research.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
